A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 31 Oct 2017
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Enalapril
- Indications Chronic heart failure
- Focus Therapeutic Use
- Acronyms PARALLEL-HF
- Sponsors Novartis; Novartis Pharmaceuticals
- 18 Aug 2017 Planned End Date changed from 24 Nov 2018 to 26 Nov 2018.
- 10 Jun 2017 Biomarkers information updated
- 17 Jan 2017 Status changed from recruiting to active, no longer recruiting.